{"id":4376,"date":"2025-05-23T11:28:15","date_gmt":"2025-05-23T17:28:15","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=4376"},"modified":"2025-05-24T00:39:05","modified_gmt":"2025-05-24T06:39:05","slug":"the-utility-of-futility","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/05\/23\/4376\/the-utility-of-futility\/","title":{"rendered":"THE UTILITY OF FUTILITY"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Companies can stop studies before reaching projected enrollment numbers.  It could be a decision based on a planned interim analysis (IA) or it could be for  \u2018administrative\u2019 reasons.  The latter may not indicate that a company has fallen on hard times financially; it could be the result of operational problems with recruitment, or in response to regulatory changes, or due to an outside event like Covid.<\/p>\n\n\n\n

Usually a DSMB handles the unblinded data review and IA.  A safety review is always done with particular attention to deaths, premature discontinuations, SAEs and AESIs, Hy\u2019s Law cases, etc.  DSMB members also need access to efficacy data to weigh risks and benefits, ie, the therapeutic index of a new drug.  This can be a particularly difficult for NCEs going for their first efficacy testing.<\/p>\n\n\n\n

The purpose of a futility analysis is to stop a trial if a benefit seems unlikely to materialize upon further enrollment.  Clearly, a trial should not run to completion when early test results indicate that patients may not benefit.  <\/p>\n\n\n\n

Timing of the first IA needs to be carefully selected  to ensure sufficient information on outcomes, enough to capture an emerging efficacy trend[1]<\/a>,[2]<\/a>,[3]<\/a><\/p>\n\n\n\n

The topic of our blog today centers on the operational aspects of conducting an IA in the course of an ongoing study.  We would argue not to stop a study, even if the first IA indicates futility.  We would rather put a study on temporary hold, esp. those with brisk enrollment as a single patient outcome can change the assessment in small sample sizes.<\/p>\n\n\n\n

Timing of the 1st IA is extremely important as it sets the smallest possible trial size and requires the most extreme results<\/p>K Viele. Interpretation of Trials that Stop Early. JAMA 2016, 315:1646<\/cite><\/blockquote><\/figure>\n\n\n\n

Let me explain.  Stopping a study often means stopping an entire program, and a lot depends on getting it right. Determination of futility may be based on very few cases 4<\/sup>. <\/p>\n\n\n\n

More information accumulates between time of data cut-off and the time the DSMB provides its verdict.   Why not look at the totality of accrued efficacy data, including supporting and secondary endpoints, run a per-protocol analysis of PP valid cases and not just of the ITT population?  Data from patients with incomplete treatment should not be ignored.<\/p>\n\n\n\n

The operational aspects of the IA process should be taken into account.  Too often it is assumed that data cut-off, data analysis and declaring futility all happen instantaneously and simultaneously.  This is never the case.<\/p>\n\n\n\n

Once a certain cut-off date is reached, several operational steps still need to be completed, all of which take time.  A study continues recruiting patients as noone wants to stop a trial awaiting the outcome of the IA.  The longer the data cleaning continues, the more patients and information accrue after data cut-off.<\/p>\n\n\n\n

Verification is time consuming but a necessary task before a DSMB can be convened and a company can make a decision.  Therefore, the IA population becomes a subset of what is actually available at the time when a company, based on DSMB recommendation, accepts or rejects the futility analysis and stops a trial for good.<\/p>\n\n\n\n

The operational work takes time, effort and money even for small trials.  Here are a few examples:<\/p>\n\n\n\n